NORTH LIBERTY, Iowa, Aug. 25 /PRNewswire/ — KemPharm, Inc.
announced today that it has received a Notice of Issuance from the
United States Patent and Trademark Office (USPTO) for its patent
application entitled “Non-Standard Amino Acid Conjugates of
Amphetamine and Processes for Making and Using the Same”, U.S.
Patent No. 7,776,917 B2. This patent, combined with
KemPharm’s recently issued U.S. Patent No. 7,772,222, provides
broad protection of the Company’s Ligand Activated Therapy (LAT)
prodrug technology platform and its application to the treatment of
Attention Deficit – Hyperactivity Disorder. The patent
covers the Company’s lead clinical candidate KP106, a new chemical
entity (NCE) composed of the active pharmaceutical compound
d-amphetamine and a ligand, which recently successfully
completed a Phase 1 clinical trial.
“This second Notice of Issuance within a week of our first
patent, reinforces our strong intellectual property position
covering KP106 and other potential ADHD drugs derived from our LAT
technology,” stated Travis Mickle, Ph.D., President & CSO for
KemPharm. “Our prodrug platform continues to deliver on all fronts
in ADHD as well as other indications, and we are excited to secure
the necessary protection that will allow us to fully develop and
commercialize our discoveries.”
“We have placed patent protection as a strategic priority from
the inception of every program, so it is great to see that our
efforts are being rewarded,” added Sven Guenther, Ph.D., Vice
President of Research. “The nature of LAT can lend itself to
generating a wide range of prodrugs with diverse pharmacological
and physicochemical properties that represent distinct and
non-obvious changes from the parent drugs. These unique
attributes enable us to pursue and receive protection from the
USPTO.”
About KP106KP106, KemPharm’s lead prodrug candidate for the
treatment of ADHD, is composed of d
‘/>”/>
